louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00147992: Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction
Official title: Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. A Retrospective Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Implants
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2005-09-07
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is an evaluation of the survival of the implants and bridges, quality of prosthetic work and patient satisfaction after immediate loading of the implants in a totally edentate upper and lower jaw.

Detailed description: This study is an evaluation of the survival of the implants and bridges, quality of prosthetic work and patient satisfaction after immediate loading of the implants in a totally edentate upper and lower jaw.

Eligibility criteria: Inclusion Criteria:

* 18-90 years old

Exclusion Criteria:

* Medical risk patients

Primary outcomes:
measure: Survival of implants and bridges
timeFrame: At beginning until last follow up
Secondary outcomes:
measure: Quality of prosthetic work
timeFrame: At end of follow up
measure: Patient satisfaction
timeFrame: At end of follow up.
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Hugo De Bruyn, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03910192: Mindfulness to Reduce Ambulatory Hypertension in Atrial Fibrillation
Official title: Mindfulness-based Coaching to Reduce Abnormal Nocturnal Hypertension in Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrial Fibrillation
Hypertension
Mindfulness
Cardiovascular Risk Reduction
Lead sponsor: York University
Sponsor class: OTHER
Collaborators: name: Southlake Regional Health Centre
First posted: 2019-04-10
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effectiveness of a 16 week mindfulness-based coaching program compared to a cardiovascular risk reduction education program.

Both groups will undergo 24-hour ambulatory blood pressure monitoring, along with assessments of psychological measures (see bellow) at study baseline, midpoint (8 weeks), and conclusion (16 weeks).

In addition, both groups will also undergo 24-hour Holter monitoring assessments at study beginning and conclusion to assess possible episodes of atrial tachyarrhythmia during the assessed interval.


Eligibility criteria: Inclusion Criteria:

* Age 50-80
* Diagnosed Atrial Fibrillation
* Night time (Sleep Time) Systolic Blood Pressure≥120 OR Daytime (awake) Systolic Blood Pressure ≥ 135
* Able and Willing to sign Informed Consent Form

Exclusion Criteria:

* Scheduled for Surgery

Primary outcomes:
measure: Night time (Sleep) Systolic Blood Pressure
timeFrame: 16 weeks
measure: Daytime time (Awake) Systolic Blood Pressure
timeFrame: 16 Weeks
Secondary outcomes:
measure: Nocturnal Dipping
timeFrame: 16 Weeks
measure: Atrial Tachyarrhythmia Episodes
timeFrame: 16 Weeks
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: 16 Weeks
measure: Profile of Mood States (POMS-SF)
timeFrame: 16 Weeks
measure: Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF)
timeFrame: 16 Weeks
measure: SF-12 v2 Health Survey
timeFrame: 16 Weeks
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 16 Weeks
measure: Cardiac Anxiety Questionnaire (CAQ)
timeFrame: 16 Weeks
Other outcomes:
Locations:
city: Newmarket
country: Canada
facility: Southlake Regional Health Centre
state: Ontario
Study officials:
affiliation: York Univrsity
name: Paul Ritvo, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04627792: Improving Child Mental Health Service Utilization in Ibadan
Official title: Improving Child Mental Health Service Utilization in Ibadan Nigeria Using a Community Based Participatory Research Approach
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mental Health Issue
Lead sponsor: Howard University
Sponsor class: OTHER
Collaborators: name: University College Hospital, Ibadan
First posted: 2020-11-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The investigators will develop and evaluate a community-based participatory intervention that will be principally guided by the model we test and confirm in Aim 1. To meet this second aim, ten guardian consultants will co-develop and co-implement a group intervention whose goal is to increase 100 guardians' recognition and knowledge of CAMH problems, perceived need for CAMH services, and willingness to use accessible services at UCH. The investigators will also evaluate the process of developing, planning, and administering a CBP intervention in Nigeria and draw broader implications for CBP programming in other LMICs.

Detailed description: One hundred participants will be randomly recruited from the cohort of guardians who completed the interview in Phase 1 and expressed interest in participating in an intervention. The investigators will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point.127 The latter group will serve as a control in the first part of the intervention plan, and the roles will be switched in the second part. The investigators will initially propose 4 intervention sessions, each comprised of 2 meetings, lasting 1.5 hours each for 25 guardians. Two sessions will be conducted concurrently for Group 1 (n=50) followed by 2 sessions concurrently conducted for Group 2 (n=50). The program outcomes - guardian recognition and knowledge of CAMH problems, the perceived need for CAMH services, and willingness to use accessible CAMH services - will be measured with the same instruments administered in Aim 1

Eligibility criteria: Inclusion Criteria:

* Participated in Phase 1 of student (participated in structured interview)

Exclusion Criteria:

-

Primary outcomes:
measure: Guardian recognition and knowledge of CAMH problems
timeFrame: up to 2 months
measure: Perceived need for CAMH services
timeFrame: up to 2 months
measure: Willingness to use accessible CAMH services
timeFrame: up to 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Howard University
name: Ezer Kang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07004192: The Role of hCG in Thawed Embryo Transfer
Official title: The Role of hCG in Thawed Embryo Transfer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Infertility (IVF Patients)
Keywords: Thawed embryo transfer
Lead sponsor: Fertility Center of Las Vegas
Sponsor class: INDUSTRY
First posted: 2025-06-04
Enrollment: 220
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Detailed description: The current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. This should be reliably achieved by administering an injection of hCG in one study arm, while the other study arm has identical treatment except for omitting the hCG.

Eligibility criteria: Inclusion Criteria:

1. Female adult expecting to receive transfer of a thawed embryo.
2. At least one available frozen blastocyst of transferrable quality.
3. Non-menopausal female with at least one antral follicle.
4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

Exclusion Criteria:

1. Minors (age\<18 years).
2. Use of embryo(s) frozen at another center.
3. Patient insistent on transfer of two embryos.
4. Patient or partner unable to provide informed consent in English.
5. Patient already enrolled in any other research study for her embryo transfer.
6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy.
7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.

Primary outcomes:
measure: Blood pressure
timeFrame: Third trimester of pregnancy
Secondary outcomes:
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: Fertility Center of Las Vegas
state: Nevada
Study officials:
References:
Clinical trial NCT00353392: Q-Switched Nd:YAG in Macular Amyloidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Macular Amyloidosis
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-07-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.

Detailed description: We treat the macular amyloidosis cases by Q-Switched Nd:YAG Laser and compare the before and after treatment situation by the photos and colorimetric assessment.

Eligibility criteria: Inclusion Criteria:

* Macular amyloidosis confirmed cases

Exclusion Criteria:

* Pregnancy and breast feeding
* Over 18 years old

Primary outcomes:
measure: Visual and colorimetric assessment
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Skin Research Center, Shaheed Beheshti Medical University
Study officials:
affiliation: Shahid Beheshti University of Medical Sciences
name: Nima Ostovari, M.D.
role: STUDY_DIRECTOR
affiliation: Shaheed Beheshti Medica University
name: Parviz Toossi, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00487292: Naps and Pulses of Bright Light in Shift Workers
Official title: The Effects of a Combination of Napping and Bright Light Pulses on Shift Workers Sleepiness at the Wheel A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep
Keywords: accidents
shift work
sleepiness
naps
bright light pulses
sleep
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: University of Paris 5 - Rene Descartes
First posted: 2007-06-18
Enrollment: 9
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Design: paired trials without and with naps and bright light. Setting: Real driving on a private road circuit. Environmental controlled car. Participants: 9 shift workers on tree shifts (morning-afternoon-night) Measurements: Sleepiness at the wheel was measured by ambulatory polysomnography and assessed using 30 seconds segments of recordings when the percentage of theta EEG was at least 50% (15 seconds) of the period recorded. Subjects were also called to rate their sleepiness on the 7-point Stanford Sleepiness Scale (SSS).

Intervention: Participants drove the same car on two similar 24 hours periods of work, with three pilots in each shift (morning, afternoon, night), separated by three weeks. During the baseline period, the subjects were told to manage their rest as they usually do in the real life. During the second experimental period, they had to rest lied in a dark room during two naps of 20 minutes and then exposed to bright light pulse (5000 lux) during 10 minutes.

Detailed description: Results are submitted to publication

Eligibility criteria: Inclusion Criteria:

* A professional experience of at least one year

Exclusion Criteria:

* With an history of chronic disease,treatments (or toxic)
* Subjects with a suspicion of sleep disorders
* Snorers

Primary outcomes:
measure: EEG sleepiness at the wheel
timeFrame: two periods of 8 hours driving
Secondary outcomes:
measure: subjective sleepiness at the stanford sleepinesss scale
timeFrame: two periods of 8 hours driving
Other outcomes:
Locations:
city: Paris
country: France
facility: Centre du Sommeil Hôtel Dieu de Paris, 1 place Parvis Notre Dame
Study officials:
affiliation: Centre du Sommeil Hotel Dieu
name: damien leger, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Hopital Pellegrin Bordeaux
name: pierre philip, M.D, Ph.D
role: STUDY_DIRECTOR
References:
citation: Leger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, Pribil C, El Hasnaoui A, Bousquet J. Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch Intern Med. 2006 Sep 18;166(16):1744-8. doi: 10.1001/archinte.166.16.1744.
citation: Philip P, Taillard J, Moore N, Delord S, Valtat C, Sagaspe P, Bioulac B. The effects of coffee and napping on nighttime highway driving: a randomized trial. Ann Intern Med. 2006 Jun 6;144(11):785-91. doi: 10.7326/0003-4819-144-11-200606060-00004.
Clinical trial NCT02599792: Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656
Official title: A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Safety and Pharmacokinetics
Lead sponsor: Concert Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2015-11-09
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and multiple-ascending doses of CTP-656 dosed for 7 days.

Detailed description: This two-part study will assess in healthy male and female subjects a solid oral dose formulation of CTP-656 vs. Kalydeco® and the safety, tolerability and pharmacokinetic profiles of escalating CTP-656 solid oral doses following 7 days of dosing. In Part B, three doses of CTP-656 ranging from 75 mg up to 300 mg per day will be studied.

Eligibility criteria: Inclusion Criteria:

* Healthy adults between 18 and 50 years of age, inclusive
* Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at screening

Exclusion Criteria:

* History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of Gilbert's syndrome or gastrointestinal (GI) conditions
* PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcF interval \> 450 msec obtained at screening visit or prior to the first dose of study drug
* Liver function tests greater than the upper limit of normal.
* Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening
* Urinalysis positive for greater than trace blood, protein or glucose
* A positive screen for alcohol, drugs of abuse, or tobacco use.
* Inability to comply with food and beverage restrictions during study participation.
* Donation or blood collection or acute loss of blood prior to screening.

Primary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 7 days
measure: Measure exposure of test articles using area under the concentration time curve (AUC)
timeFrame: 96 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Adelaide
country: Australia
state: South Australia
Study officials:
affiliation: Concert Pharmaceuticals, Inc.
name: Lana Pilja
role: STUDY_DIRECTOR
References:
Clinical trial NCT02000492: Frequent Ballgames Training for 9-11 Year Old Schoolchildren
Official title: Intense School Based Physical Activity - Physiological, Cognitive and Sociological Aspects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Body Composition
Echocardiography
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: University Hospital, Gentofte, Copenhagen
First posted: 2013-12-04
Enrollment: 423
Sex: ALL
Minimum age (years): 9
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Inactivity among schoolchildren is a challenge to public health and for the municipality in particular. This study´s aim is to evaluate the cognitive and physical as well as social and fitness adaptations, and learning outcomes of short- and long term ball training for 9-11 years old girls and boys, and to determine to what extend the organisation (5x12 minutes og 3x40 minute a week) and type of training (ball games, circuit training or running) influence the magnitude of response.


Eligibility criteria: Inclusion Criteria:

* 9-11 years old girls and boys in 3rd grade in schools in Frederikssund and Copenhagen

Exclusion Criteria:

* Children with severe mental or physical disabilities

Primary outcomes:
measure: Cardiac function
timeFrame: 1 year
measure: Body composition
timeFrame: 1 year
Secondary outcomes:
measure: Cognitive effect
timeFrame: 1 year
Other outcomes:
measure: Social effects
timeFrame: 1 Year
Locations:
city: Frederikssund
country: Denmark
facility: Municipality of Frederikssund
Study officials:
affiliation: Centre of team sports and health, University of Copenhagen
name: Peter Krustrup, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: University hospital og Gentofte
name: Peter R Hansen, dr Msc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Larsen MN, Madsen M, Nielsen CM, Manniche V, Hansen L, Bangsbo J, Krustrup P, Hansen PR. Cardiovascular adaptations after 10 months of daily 12-min bouts of intense school-based physical training for 8-10-year-old children. Prog Cardiovasc Dis. 2020 Nov-Dec;63(6):813-817. doi: 10.1016/j.pcad.2020.05.011. Epub 2020 Jun 1.
citation: Larsen MN, Nielsen CM, Helge EW, Madsen M, Manniche V, Hansen L, Hansen PR, Bangsbo J, Krustrup P. Positive effects on bone mineralisation and muscular fitness after 10 months of intense school-based physical training for children aged 8-10 years: the FIT FIRST randomised controlled trial. Br J Sports Med. 2018 Feb;52(4):254-260. doi: 10.1136/bjsports-2016-096219. Epub 2016 Jun 13.
Clinical trial NCT04757792: Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Official title: Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Disease
Keywords: COVID-19
NSAID
Aspirin
Mortality
Lead sponsor: Benha University
Sponsor class: OTHER
Collaborators: name: Tanta University
name: Cairo University
First posted: 2021-02-17
Enrollment: 475
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with diagnosis of COVID-19

Brief summary: Retrospective multicenter study to evaluate the data of COVID-19 patients who were admitted to university hospitals in relation to their recent administration or maintenance on non-steroidal anti-inflammatory drugs (NSAID) prior to have COVID-19 disease and to analyze it in relation to outcome of these patients.

Detailed description: The data contained in hospital registry were collected, categorized into demographic, previous medical history, the use of NSAID as maintenance therapy or its recent administration before diagnosis of COVID-19 disease, presenting manifestations, laboratory and CT findings, applied therapies or interventions. Outcomes will be categorized as survival and non-survival outcome. Survivors will be subdivided as complete recovery or recovery with getting new morbidities. Mortality was subdivided as total hospital and ICU mortality. Data will be statistically analyzed in relation to outcomes

Eligibility criteria: Inclusion Criteria:

* assured diagnosis of COVID-19 by RT-PCR

Exclusion Criteria:

* No

Primary outcomes:
measure: Mortality rate
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Faculty of Medicine
state: Qalubia
Study officials:
affiliation: Faculty of medicine, Banha University, Egypt
name: Adel Alkholy, Prof
role: PRINCIPAL_INVESTIGATOR
References: